EZH2 expression in diffuse large B-cell lymphoma: clinicopathological associations and relationship with survival
Purpose: Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator implicated in the pathogenesis of diffuse large B-cell lymphoma, but the prognostic value of its protein expression is uncertain. We evaluated EZH2 expression and its associations with clinicopathological features and survival.Materials and Methods: We retrospectively studied 50 patients with diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. EZH2 expression was assessed by immunohistochemistry using an H-score and classified as high (≥150) or low (
Authors
- Mehmet Mutlu Kıdı (ORCID: https://orcid.org/0000-0002-4750-720X)
- Tuğba Toyran (ORCID: https://orcid.org/0000-0001-9135-0265)
- Ertuğrul Bayram (ORCID: https://orcid.org/0000-0001-8713-7613)
- Mehmet Türker (ORCID: https://orcid.org/0000-0003-4163-917X)
- Melek Ergin (ORCID: https://orcid.org/0000-0003-1744-839X)
- Tolga Köşeci (ORCID: https://orcid.org/0000-0002-8696-0525)
- İsmail Oğuz Kara (ORCID: https://orcid.org/0000-0003-4963-2028)
- Sedat Biter (ORCID: https://orcid.org/0000-0002-1053-0668)
- Yasemin Aydınalp Camadan (ORCID: https://orcid.org/0000-0003-2435-368X)
- Berksoy Şahin
- Hatice Asoglu (ORCID: https://orcid.org/0009-0000-1366-5552)
Institutions
- Şanlıurfa Mehmet Akif İnan Eğitim ve Araştırma Hastanesi (TR)
- Cukurova University (TR)
Publication Details
- Journal
- Çukurova medical journal (Online)/Çukurova medical journal
- Published
- 2026-09-30
- DOI
- https://doi.org/10.17826/cumj.2001681
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.00